Lichen Planus Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight

 Breaking News
  • No posts were found

Lichen Planus Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight

Lichen Planus Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration & Companies by DelveInsight
Lichen Planus Pipeline
Lichen Planus companies are Novartis, Amgen, Kiniksa Pharmaceuticals, AFYX Therapeutics, Regeneus, and others.

(Albany, United States) As per DelveInsight’s assessment, globally, Lichen Planus pipeline constitutes 6+ key companies continuously working towards developing 6+ Lichen Planus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“Lichen Planus Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Lichen Planus Market.

The Lichen Planus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample Report here @ Lichen Planus Pipeline Analysis

 

Some of the key takeaways from the Lichen Planus Pipeline Report:

  • Lichen Planus Companies across the globe are diligently working toward developing novel Lichen Planus treatment therapies with a considerable amount of success over the years. 
  • Lichen Planus companies working in the treatment market are Novartis, Amgen, Kiniksa Pharmaceuticals, AFYX Therapeutics, Regeneus, and others, are developing therapies for the Lichen Planus treatment.
  • Emerging Lichen Planus therapies such as Rivelin-CLO, LP-10, and others are expected to have a significant impact on the Lichen Planus market in the coming years.  
  • In February 2024, Stratpharma AG announced results of a VALOR: Vaginal Atrophy & Long-term Observation of Recovery (VALOR)
  • In April 2024, Koite Health Oy announced results of a Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Topical Corticosteroid Treatment in Patients With Gingival Involvement of Oral Lichen Planus – a Randomized Study
  • In January 2024, Lipella Pharmaceuticals announced results of a Multicenter, Dose-Ranging Trial Evaluating the Safety, Tolerability, and Efficacy of LP-10 in Subjects With Symptomatic Oral Lichen Planus 

 

Lichen Planus Overview

Lichen planus is a chronic inflammatory condition affecting the skin and mucous membranes. It is characterized by itchy, flat-topped, purplish lesions on the skin and white, lacy patches in the mouth. The exact cause of lichen planus is unknown, but it is believed to be an autoimmune disorder where the immune system mistakenly attacks the skin and mucous membrane cells.

On the skin, lichen planus commonly appears on the wrists, ankles, and lower back, presenting as polygonal, purplish, itchy bumps. Oral lichen planus typically affects the inside of the cheeks, gums, and tongue, manifesting as white, lacy patches or painful sores. Other areas that can be affected include the nails, scalp, and genital region.

Lichen Planus Diagnosis is primarily clinical, based on the characteristic appearance of the lesions. A biopsy may be performed to confirm the diagnosis and rule out other conditions.

Lichen Planus Treatment aims to relieve symptoms, as there is no cure for lichen planus. Topical corticosteroids are the first line of treatment to reduce inflammation and itching. Severe cases may require systemic treatments like oral corticosteroids, retinoids, or immunosuppressive drugs. Good oral hygiene and avoiding triggers such as stress and certain medications can help manage the condition.

While lichen planus can be chronic and recurrent, it is generally not life-threatening. Regular follow-up with a healthcare provider is important to monitor and manage the condition effectively.

 

Get a Free Sample PDF Report to know more about Lichen Planus Pipeline Therapeutic Assessment- Lichen Planus Treatment Market

 

Lichen Planus Route of Administration

Lichen Planus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

 

Lichen Planus Molecule Type

Lichen Planus Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Lichen Planus Pipeline Therapeutics Assessment

  • Lichen Planus Assessment by Product Type
  • Lichen Planus By Stage and Product Type
  • Lichen Planus Assessment by Route of Administration
  • Lichen Planus By Stage and Route of Administration
  • Lichen Planus Assessment by Molecule Type
  • Lichen Planus by Stage and Molecule Type

 

DelveInsight’s Lichen Planus Report covers around 6+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Lichen Planus product details are provided in the report. Download the Lichen Planus pipeline report to learn more about the emerging Lichen Planus therapies- Lichen Planus Therapeutic Assessment

 

Lichen Planus Pipeline Analysis:

The Lichen Planus pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Lichen Planus with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Lichen Planus Treatment.
  • Lichen Planus key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Lichen Planus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Lichen Planus market.

 

Download Sample PDF Report to know more about Lichen Planus drugs and therapies- Lichen Planus Clinical Trials and FDA Approvals

  

Scope of Lichen Planus Pipeline Drug Insight    

  • Coverage: Global
  • Key Lichen Planus Companies: Novartis, Amgen, Kiniksa Pharmaceuticals, AFYX Therapeutics, Regeneus, and others.
  • Key Lichen Planus Therapies: Rivelin-CLO, LP-10, and others.
  • Lichen Planus Therapeutic Assessment: Lichen Planus current marketed and Lichen Planus emerging therapies
  • Lichen Planus Market Dynamics: Lichen Planus market drivers and Lichen Planus market barriers 

 

Request for Sample PDF Report for Lichen Planus Pipeline Assessment and clinical trials – Lichen Planus Drugs and Therapies

 

Table of Contents

  1. Lichen Planus Report Introduction
  2. Lichen Planus Executive Summary
  3. Lichen Planus Overview       
  4. Lichen Planus- Analytical Perspective In-depth Commercial Assessment
  5. Lichen Planus Pipeline Therapeutics
  6. Lichen Planus Late Stage Products (Phase II/III)
  7. Lichen Planus Mid Stage Products (Phase II)
  8. Lichen Planus Early Stage Products (Phase I)
  9. Lichen Planus Preclinical Stage Products
  10. Lichen Planus Therapeutics Assessment
  11. Lichen Planus Inactive Products
  12. Company-University Collaborations (Licensing/Partnering) Analysis
  13. Lichen Planus Companies
  14. Lichen Planus Key Products
  15. Lichen Planus Unmet Needs
  16. 16 . Lichen Planus Market Drivers and Barriers
  17. Lichen Planus Future Perspectives and Conclusion
  18. Lichen Planus Analyst Views
  19. Appendix
  20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Categories